Citations 3
EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412)
Cohen, Jonathon B. , Robertson, May C., David, Kevin A. , Fenske, Timothy S. , Palmisano, N., Svoboda, Jakub , Morgan, D. , Ansell, Stephen M. , Diefenbach, Catherine , Hong, Fangxin , Ambinder, Richard F. , Robertson, M., Advani, Ranjana H. , Barta, Stefan K , Morgan, D., Karmali, Reem , Kahl, Brad S.
Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 123-124
Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.
Cohen, Jonathon B. , David, Kevin A. , Fenske, Timothy S. , Palmisano, N., Svoboda, Jakub , Ansell, Stephen M. , Diefenbach, Catherine , Hong, Fangxin , Ambinder, Richard F. , Advani, Ranjana H. , Robertson, Michael J. , Barta, Stefan K , Morgan, David , Karmali, Reem , Kahl, Brad S.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7538-7538
SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG‐ACRIN CANCER RESEARCH GROUP (E4412)
David, Kevin A. , Cohen, Jonathon B. , Roberston, M., Palmisano, N., Ambinder, Rich, Ansell, Stephen M. , Diefenbach, Catherine , Hong, Fangxin , Advani, Ranjana H. , Kahl, Brad S.
Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 84-85